TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
8/16/23 20:53 | 8/16/23 | TSHA | Taysha Gene Therapies, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Stalfort John A III | TX | D | P | 700 | 0.9000 | 0 | 778 | 67 | 1,934 | M | |||||||||||||||
7/5/22 16:11 | 7/5/22 | VRCA | Verrica Pharmaceuticals Inc. | DE | Health | Drug | Pharmaceutical Preparations | Stalfort John A III | PA | D | P | 500 | 2.10 | 0 | 238 | 52 | 700 | D | |||||||||||||||
7/8/21 18:17 | 7/6/21 | ABOS | Acumen Pharmaceuticals, Inc. | Health | BioPrd | Biological Products, (No Diag | Stalfort John A III | VA | D | P.d | 560 | 16.00 | 0 | 35 | 13 | 304 | M | ||||||||||||||||
8/17/20 16:39 | 8/13/20 | VRCA | Verrica Pharmaceuticals Inc. | DE | Health | Drug | Pharmaceutical Preparations | Stalfort Sean | PA | D | P.m | 200 | 6.41 | 0 | 31 | 7 | 462 | D | |||||||||||||||
1/7/19 20:54 | 1/7/19 | VRCA | Verrica Pharmaceuticals Inc. | DE | Health | Drug | Pharmaceutical Preparations | Stalfort Sean | PA | D | P | 96 | 10.45 | 0 | 9 | 2 | 431 | D | |||||||||||||||
12/21/18 17:07 | 12/20/18 | DOVA | Dova Pharmaceuticals Inc. | DE | Health | Drug | Pharmaceutical Preparations | Stalfort Sean | VA | D | P | 194 | 6.26 | 0 | 31 | 5 | 636 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |